
AVEO Pharmaceuticals AVEO
Quartalsbericht 2022-Q3
hinzugefügt 07.11.2022
AVEO Pharmaceuticals Zahlungsmittel 2011-2026 | AVEO
Zahlungsmittel Jährlich AVEO Pharmaceuticals
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| 70.5 M | 61.8 M | 29.8 M | 24.4 M | 14.9 M | 15.1 M | 26.6 M | 52.3 M | 50.8 M | 76.1 M | 43.5 M |
Alle Zahlen in USD-Währung
Indikatorenreichweite aus Jahresberichten
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 76.1 M | 14.9 M | 42.4 M |
Zahlungsmittel Vierteljährlich AVEO Pharmaceuticals
| 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| - | 77.4 M | - | 73.8 M | 70.5 M | 68.8 M | 74.7 M | 121 M | 61.8 M | 61.8 M | 61.8 M | 61.8 M | 29.8 M | 29.8 M | 29.8 M | 29.8 M | 24.4 M | 24.4 M | 24.4 M | 24.4 M | 14.9 M | 14.9 M | 14.9 M | 14.9 M | 15.1 M | 15.1 M | 15.1 M | 15.1 M | 26.6 M | 26.6 M | 26.6 M | 26.6 M | 52.3 M | 52.3 M | 52.3 M | 52.3 M | 50.8 M | 50.8 M | 50.8 M | 50.8 M | 76.1 M | 76.1 M | 76.1 M | 76.1 M | 43.5 M | 43.5 M | 43.5 M | 43.5 M |
Alle Zahlen in USD-Währung
Indikatorspanne aus vierteljährlicher Berichterstattung
| Höchstwert | Mindestwert | Durchschnitt |
|---|---|---|
| 121 M | 14.9 M | 45 M |
Zahlungsmittel anderer Aktien in der Pharmaeinzelhändler
| Name | Zahlungsmittel | Preis | % 24h | Marktkapitalisierung | Land | |
|---|---|---|---|---|---|---|
|
MorphoSys AG
MOR
|
158 M | - | 2.43 % | $ 254 M | ||
|
ARCA biopharma
ABIO
|
61.6 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
16.4 M | - | 5.93 % | $ 314 M | ||
|
Albireo Pharma
ALBO
|
248 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
12.9 M | - | 10.36 % | $ 9.8 M | ||
|
I-Mab
IMAB
|
4.76 B | - | - | $ 866 M | ||
|
Genfit SA
GNFT
|
81.8 M | - | 2.54 % | $ 160 B | ||
|
Biophytis SA
BPTS
|
5.57 M | - | -13.47 % | $ 169 M | ||
|
Ascendis Pharma A/S
ASND
|
616 M | $ 220.94 | 2.51 % | $ 5 B | ||
|
Aptinyx
APTX
|
56.2 M | - | -39.0 % | $ 4.57 M | ||
|
Midatech Pharma plc
MTP
|
1.67 M | - | -18.52 % | $ 27.3 M | ||
|
Amphastar Pharmaceuticals
AMPH
|
170 M | $ 19.7 | 2.44 % | $ 921 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
46.4 M | - | - | $ 26.5 M | ||
|
Mesoblast Limited
MESO
|
60.4 M | $ 15.54 | 8.48 % | $ 10.1 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.41 M | - | - | $ 7.46 M | ||
|
AgeX Therapeutics
AGE
|
345 K | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
30 M | - | -24.86 % | $ 820 K | ||
|
Atreca
BCEL
|
30.8 M | - | -11.76 % | $ 5.79 M | ||
|
Acasti Pharma
ACST
|
22.1 M | - | 4.01 % | $ 150 M | ||
|
BeiGene, Ltd.
BGNE
|
4.55 B | - | 0.49 % | $ 251 B | ||
|
Mirum Pharmaceuticals
MIRM
|
297 M | $ 90.9 | 3.44 % | $ 4.56 B | ||
|
bluebird bio
BLUE
|
222 M | - | - | $ 546 M | ||
|
Cara Therapeutics
CARA
|
51.8 M | - | -3.03 % | $ 260 M | ||
|
Adverum Biotechnologies
ADVM
|
60.7 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
2.33 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
4.88 M | - | -9.65 % | $ 45.9 M | ||
|
MediciNova
MNOV
|
30.8 M | $ 1.44 | -0.68 % | $ 70.7 M | ||
|
Avenue Therapeutics
ATXI
|
2.59 M | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
240 M | $ 1.36 | 3.03 % | $ 347 M | ||
|
CytomX Therapeutics
CTMX
|
12.7 M | $ 4.41 | 3.98 % | $ 608 M | ||
|
Cyclacel Pharmaceuticals
CYCC
|
3.14 M | - | -5.98 % | $ 34.1 M | ||
|
ChemoCentryx
CCXI
|
50 M | - | - | $ 3.74 B | ||
|
Merck & Co.
MRK
|
14.6 B | $ 118.9 | 2.17 % | $ 297 B | ||
|
Dynavax Technologies Corporation
DVAX
|
95.9 M | - | - | $ 2.02 B | ||
|
BioDelivery Sciences International
BDSI
|
112 M | - | -4.8 % | $ 255 M | ||
|
Enochian Biosciences
ENOB
|
92.7 K | - | - | $ 40.5 M | ||
|
Aeglea BioTherapeutics
AGLE
|
85.7 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
811 M | - | - | $ 867 M | ||
|
Bellerophon Therapeutics
BLPH
|
6.92 M | - | -74.18 % | $ 955 K | ||
|
Akero Therapeutics
AKRO
|
340 M | - | - | $ 3.67 B | ||
|
Neurocrine Biosciences
NBIX
|
713 M | $ 131.82 | 3.1 % | $ 13.1 B | ||
|
Arbutus Biopharma Corporation
ABUS
|
18 M | $ 4.56 | 5.68 % | $ 874 M | ||
|
Homology Medicines
FIXX
|
48.3 M | - | 0.77 % | $ 53.4 M | ||
|
Akouos
AKUS
|
122 M | - | 0.23 % | $ 488 M | ||
|
AIkido Pharma
AIKI
|
4.08 M | - | 1.93 % | $ 17.4 M | ||
|
Allakos
ALLK
|
66.4 M | - | - | $ 28.6 M |